TSH Norms in Pregnancy: Trimester Targets and Clinical Tactics

Key points

Pregnancy needs its own TSH norms, and the ATA 2017 reference points (PMID 28056690) help reduce risks for mother and fetus. TSH is given in mIU/L (the same as µIU/mL).

🌀

Why norms are different: thyroid physiology in pregnancy

▸hCG mimics TSH — in the first trimester, human chorionic gonadotropin has structural homology with thyrotropin and directly stimulates the thyroid via the TSH receptor. Physiologically this causes TSH to fall at the hCG peak (weeks 8–14) — the classical observation by Glinoer (PMID 9183570). ▸Estrogens raise TBG — thyroxine-binding globulin increases 1.5–2-fold. Total T4 rises while free fT4 remains relatively stable. ▸Iodine requirement increases by 50% — driven by renal clearance and fetal need. ▸The fetus depends on maternal hormone until weeks 18–20 — the fetal thyroid does not begin meaningful function until the second half of pregnancy.

The clinical principle that follows: the upper TSH bound in pregnancy is lower than in non-pregnant women.

🌀

Trimester-specific TSH targets

Per the 2017 ATA Guideline (Alexander et al., PMID 28056690), the normal range and the treatment target are not the same thing:

▸Normal range in pregnancy — the pregnancy-specific intervals provided by your laboratory (or by a lab with a similar population and the same assay) ▸If no such range exists — an upper limit of about 4.0 mIU/L; for most assays this is roughly 0.5 mIU/L below the non-pregnant upper limit ▸Planning pregnancy on levothyroxine — TSH between the lower reference limit and 2.5 mIU/L ▸Pregnant on levothyroxine — lower half of the pregnancy-specific range; if unavailable, < 2.5 mIU/L

With positive anti-TPO, the threshold for a treatment decision is lower: at TSH above 2.5 mIU/L levothyroxine may be considered, and above the pregnancy-specific range it is recommended (ATA 2017, Recommendation 29). Anti-TPO positive patients have reduced thyroid functional reserve and respond worse to the rising demands of pregnancy at any given TSH.

Taking the non-pregnant range from the generic lab report as the pregnancy norm is an error. The opposite error is calling TSH 2.5–4.0 mIU/L hypothyroidism in every pregnant woman: 2.5 is a treatment target, not the edge of normal.

🌀

When to start levothyroxine

Initiation tactics during pregnancy (ATA 2017, Recommendations 27–29; at TSH > 2.5 mIU/L, anti-TPO is checked first):

▸Overt hypothyroidism (TSH above the pregnancy range + low fT4) — treatment is mandatory. Start without delay; the dose is set by the physician. ▸TSH > 10 mIU/L — levothyroxine is recommended even with normal fT4 and negative anti-TPO. ▸TSH above the pregnancy range + anti-TPO positive — levothyroxine is recommended. ▸TSH above the pregnancy range but < 10 mIU/L + anti-TPO negative — levothyroxine may be considered (weak recommendation). ▸TSH from 2.5 mIU/L to the upper limit of the pregnancy range + anti-TPO positive — levothyroxine may be considered (weak recommendation); the decision is individual and takes obstetric history into account.

When treatment is indicated, start it right away. "Wait and see" is not a tactic in pregnancy thyroid management.

🌀

Why detect and treat hypothyroidism

Uncompensated hypothyroidism during pregnancy is associated with increased rates of:

▸Spontaneous miscarriage — increased risk ▸Gestational diabetes ▸Hypertension and preeclampsia ▸Preterm birth ▸Placental abruption ▸Postpartum hemorrhage ▸Reduced child cognitive development — children of women with severe untreated hypothyroidism in the 2nd trimester scored 7 points lower on IQ testing (Haddow et al., PMID 10451459)

This evidence base is why ATA 2017 recommends detecting and treating hypothyroidism in pregnancy.

🌀

Anti-TPO and fertility: a standalone risk even at normal TSH

Positive anti-TPO with normal TSH is an independent risk factor for:

▸IVF failure — reduced implantation and live birth rates ▸Postpartum thyroiditis — develops in 33–50% of women with antibodies in the 1st trimester (ATA 2017)

ATA 2017 allows 25–50 µg levothyroxine with positive anti-TPO and normal TSH in two situations — prior pregnancy loss (Recommendation 14; Negro et al., PMID 16621910) and assisted reproduction/IVF (Recommendation 21); this is a weak recommendation ("may be considered"). The logic of treatment in these situations: compensate the reduced thyroid functional reserve before pregnancy demands exceed it.

More on the role of anti-TPO, selenium, and vitamin D in reducing antibody titers — in Iodine and thyroid: 5-step protocol.

🌀

Iodine in pregnancy: dose and form

A pregnant woman needs about 250 µg of iodine per day (ATA 2017, Recommendation 5; WHO) — this is total intake from food and supplements combined, not the dose of a tablet.

▸A 150 µg daily iodine supplement as potassium iodide — in most regions ATA recommends it for every woman planning pregnancy or pregnant (Recommendation 6). Ideally start 3 months before planned conception. ▸Women already on levothyroxine or treated for hyperthyroidism do not need to start an iodine supplement (Recommendation 8). ▸NOT kelp, NOT Lugol's solution — herbal and alcohol-based preparations give uncontrolled doses (from 150 µg to 6 mg per drop) and risk iodine-induced thyroiditis. Sustained intake above 500 µg/day should be avoided in pregnancy (Recommendation 10). ▸In autoimmune thyroiditis (anti-TPO positive) — the ATA recommendation is the same: a 150 µg daily supplement; antibody positivity is not named as an exception.

🌀

The full panel: what to check and when

Minimum lab workup for a pregnant woman with hypothyroidism or AIT:

▸At diagnosis: TSH, fT4, anti-TPO, anti-Tg ▸At preconception: + fT3, ferritin, vitamin D, selenium (if available), urinary iodine (when indicated) ▸On levothyroxine therapy and with positive anti-TPO: TSH + fT4 about every 4 weeks until mid-pregnancy and at least once near week 30 (ATA 2017, Recommendation 33) ▸Who should have TSH checked early in pregnancy (ATA 2017): age > 30, family history of autoimmune thyroid disease, positive anti-TPO, type 1 diabetes, infertility or prior pregnancy loss, BMI ≥ 40, amiodarone or lithium, living in an iodine-deficient region

Levothyroxine dose during pregnancy typically increases by 25–30% from baseline due to increased demand (Abalovich et al., PMID 17948378). If a woman conceives on an already titrated dose, the increase is often needed by weeks 5–6. ATA 2017 advises increasing the dose by about 20–30% as soon as pregnancy is confirmed and informing the physician; a convenient way is two extra daily doses per week. In the randomised THERAPY trial (48 women), this increase right after pregnancy confirmation kept TSH from rising above 5.0 mIU/L throughout the 1st trimester (Yassa et al., PMID 20463094).

Levothyroxine administration rules:

▸Strictly fasting 30–60 minutes before breakfast ▸Do not combine with iron, calcium, or multivitamins with iron or calcium — they reduce absorption; keep them no closer than 4 hours to the tablet ▸Water only — not coffee, not milk

More on the deiodinase system and T4→T3 conversion that determines replacement efficacy — in T4→T3 conversion and functional hypothyroidism.

🌀

Monitoring during and after pregnancy

▸Until mid-pregnancy (~week 20) — TSH + fT4 about every 4 weeks. Peak sensitivity period for undercompensation. ▸Around week 30 — at least one more TSH check (Recommendation 33). ▸After delivery — levothyroxine returns to the pre-pregnancy dose, with TSH about 6 weeks postpartum (Recommendation 37). ▸Postpartum surveillance — TSH at 3 and 6 months postpartum, particularly in anti-TPO positive women. ▸Breastfeeding — levothyroxine is safe while breastfeeding; methimazole up to 20 mg/day and PTU up to 450 mg/day are compatible with breastfeeding. ▸Iodine while breastfeeding — the 150 µg daily supplement continues throughout breastfeeding; women on levothyroxine do not need to start it.

Postpartum thyroiditis develops in about 5% of women (1–17% across studies) within the first year after delivery. The classical triphasic course (transient thyrotoxicosis → hypothyroidism → recovery) occurs in about a quarter, another quarter have only the thyrotoxic phase, and half have only hypothyroidism (ATA 2017; Stagnaro-Green, PMID 22312089). With positive anti-TPO in the 1st trimester, postpartum thyroiditis develops in 33–50% of women, and a fraction of these episodes progress to permanent hypothyroidism. Antithyroid drugs are not needed for postpartum thyroiditis; in 10–20% of women the hypothyroidism after it remains permanent.

🌀

Hyperthyroidism and Graves' disease in pregnancy: a separate protocol

Hyperthyroidism in pregnancy is a distinct and more dangerous clinical situation that requires fundamentally different management. The prevalence of overt hyperthyroidism in pregnancy is 0.1–0.4%, and Graves' disease accounts for about 85% of cases. Untreated, it is associated with preeclampsia, maternal heart failure, preterm birth and fetal death (Cooper & Laurberg, PMID 24622372).

Diagnostic reference points:

▸TSH < 0.1 mIU/L + elevated fT4 and/or fT3 — suspected overt thyrotoxicosis. On its own, TSH 0.05–0.3 mIU/L in the 1st trimester is physiological (hCG effect, Glinoer, PMID 9183570), so an isolated low TSH without elevated fT4 is not a diagnosis. Subclinical hyperthyroidism (low TSH, normal fT4) without symptoms and without TRAb is not treated. ▸TRAb (TSH receptor antibodies) — a mandatory marker. Positive TRAb confirm Graves' disease and at the same time predict fetal/neonatal thyrotoxicosis, because IgG crosses the placenta. ATA 2017 recommends measuring TRAb in early pregnancy in women after radioiodine or thyroidectomy for Graves' disease and in those taking antithyroid drugs; if TRAb are elevated or antithyroid drugs are needed until mid-pregnancy — repeat at weeks 18–22. In remission after a course of antithyroid drugs, TRAb testing in pregnancy is not required (Recommendation 52) (PMID 28056690). Maternal TRAb can persist for years after surgery or radioiodine; negative TRAb in the 2nd trimester mean a low risk of fetal thyrotoxicosis.

Thionamide therapy — two stages by trimester:

▸Up to week 16 — propylthiouracil (PTU) at a starting dose of 100–450 mg/day in 3 doses. Methimazole in the 1st trimester is associated with severe embryopathies (aplasia cutis, esophageal/choanal atresia, omphalocele) — a risk of 2–4% versus < 0.3% for PTU. First-trimester mortality from agranulocytosis and hepatotoxicity is higher with PTU, but the embryopathic risk of methimazole outweighs it. In a Danish study (817,093 children), birth defects after early-pregnancy exposure were more frequent with both methimazole (OR 1.66) and PTU (OR 1.41) (Andersen et al., PMID 24151287). ▸After week 16 — PTU or methimazole 5–20 mg/day. PTU is associated with rare fulminant maternal hepatitis (1:10,000) requiring liver transplantation. Whether to switch from PTU to methimazole is decided individually (Recommendation 47d): a switch may temporarily worsen control. The dose ratio methimazole : PTU is about 1 : 20. ▸Target fT4 — at or slightly above the upper limit of the non-pregnant range. TSH is not used as a target — it is suppressed by hCG and does not reflect control. The lowest thionamide dose that keeps fT4 on target is safer for the fetus than aggressive lowering.

Fetal monitoring when TRAb > 3× the upper limit:

▸Ultrasound assessment of the fetal thyroid (goiter, tachycardia > 170/min, bone age, IUGR) every 4 weeks from the 2nd trimester. ▸Neonatal screening of TSH + fT4 in the first 24–72 hours of life — fetal thyrotoxicosis may manifest with a delay, as maternal thionamides are cleared while TRAb persist in the newborn.

Beta-blockers (propranolol 10–40 mg 3 times/day) are acceptable as a short course to control tachycardia at the start of therapy, but long-term use is associated with IUGR, neonatal bradycardia and hypoglycemia. Atenolol is contraindicated.

Radioiodine therapy and I-131 scintigraphy are absolutely contraindicated throughout pregnancy — the isotope accumulates in the fetal thyroid after weeks 10–12 and causes irreversible congenital hypothyroidism. Thyroidectomy, if needed (agranulocytosis on both thionamides, poor control), is best performed in the 2nd trimester. After radioiodine treatment, conception is planned no earlier than 6 months later.

🌀

Differentiating gestational transient thyrotoxicosis from Graves' disease

When TSH < 0.1 mIU/L is found in the 1st trimester, the first clinical question is whether this is physiology or Graves' disease, because the treatment is fundamentally different. A mistake is costly: gestational transient thyrotoxicosis (GTT) resolves spontaneously by weeks 14–18 and thionamides are contraindicated in it, whereas untreated Graves' disease leads to preeclampsia, preterm birth, fetal thyrotoxicosis and thyroid storm.

Key differences:

▸Symptoms before pregnancy — absent in GTT, often present in Graves'. ▸Goiter, exophthalmos — absent in GTT, often present in Graves'. ▸TRAb — negative in GTT, positive in Graves' (the main discriminator). ▸Anti-TPO — usually negative in GTT, may be positive in Graves'. ▸Hyperemesis — common in GTT, not typical of Graves'. ▸fT3/fT4 ratio — in GTT usually fT4 ↑↑ and fT3 ↑, in Graves' fT3 ↑↑↑ (T3 toxicosis is more common). ▸Course by weeks 14–18 — spontaneous normalization in GTT, persistence or worsening in Graves'. ▸Thyroid ultrasound — normal in GTT, diffuse enlargement and hypervascularity in Graves'.

Management of GTT:

▸Thionamides are NOT indicated. They cross the placenta, whereas maternal hCG stimulation does not act directly on the fetus, and the risk of iatrogenic fetal hypothyroidism outweighs the benefit. ▸Treatment is symptomatic — rehydration in hyperemesis, antiemetics (doxylamine/pyridoxine, metoclopramide when indicated), propranolol 10–20 mg 2–3 times/day as a short course for marked tachycardia and tremor. ▸TSH + fT4 every 3–4 weeks until normalization. In most patients TSH normalizes by weeks 14–18.

If thyrotoxicosis persists beyond weeks 18–20, TRAb appear or rise, or a goiter forms — the diagnosis is revised toward Graves' disease and thionamides are started.

🌀

Isolated hypothyroxinemia: low fT4 with normal TSH

Isolated hypothyroxinemia (IH) — fT4 below the trimester-specific range with TSH within the reference range — is a separate clinical category. Its prevalence is 1.3–2.4% in the 1st trimester and reaches 4–6% in the 2nd–3rd trimesters as fT4 gradually declines with advancing pregnancy.

Pathogenesis of IH:

▸Iodine deficiency — the main cause in populations with median urinary iodine < 150 µg/L. Low iodine intake limits T4 synthesis before the TSH feedback kicks in. ▸Iron deficiency (ferritin < 30 ng/mL) — thyroid peroxidase depends on iron as a heme protein. ▸Anti-TPO positivity with preserved basal TSH but reduced functional reserve. ▸Severe selenium deficiency, impairing hormone synthesis via glutathione peroxidase.

Differential diagnosis and management:

▸Confirm in the lab — repeat fT4 + TSH + anti-TPO after 2 weeks. An isolated low fT4 without repeat confirmation may be an artifact (assay-dependent interference at high TBG). Repeat against a trimester-specific range, or measure total T4: in pregnancy its normal range is ≈ 1.5 times the non-pregnant one (ATA 2017). ▸Assess deficiencies — ferritin, urinary iodine (if possible), vitamin D, selenium. ▸Iodine supplement 150 µg/day (total intake about 250 µg), as in any pregnancy, if the woman is not on levothyroxine.

The main focus in IH is preconception correction of iodine and iron status: it is the only strategy that targets the underlying mechanism and has been proven for population outcomes.

🌀

Thyroid nodules and thyroid cancer in pregnancy

Thyroid nodules are found in 3–21% of pregnant women, depending on the region and imaging method.

Diagnostic algorithm:

▸Thyroid ultrasound with TI-RADS or ATA categories — acceptable and safe in any trimester, with no radiation exposure. ▸Fine-needle aspiration biopsy (FNA) — indicated for nodules ≥ 1 cm with suspicious ultrasound features (microcalcifications, hypoechogenicity, irregular margins, taller-than-wide, extracapsular growth). The biopsy is safe at any stage of pregnancy and is done under local anesthesia. If a nodule is found in the 1st trimester and is not high-risk, the biopsy can be postponed to the 2nd trimester for convenience, but not later. ▸I-131 or Tc-99m scintigraphy is contraindicated. A "hot nodule" is not differentiated or assessed diagnostically in pregnancy.

Management by FNA result (Bethesda):

▸Bethesda I (nondiagnostic) — repeat in 6–12 weeks. ▸Bethesda II (benign) — observation, ultrasound in 6 months and after delivery. ▸Bethesda III–IV (AUS/FLUS, follicular neoplasm) — individualized, more often observation with surgery after delivery. ▸Bethesda V–VI (suspicious for cancer / papillary cancer) — consider thyroidectomy in the 2nd trimester or after delivery. Papillary thyroid cancer (PTC) is the most common type and grows slowly, and postponing surgery by 6–9 months does not worsen the prognosis in the vast majority of cases.

Radioiodine ablation (RAI) and suppressive levothyroxine therapy are postponed until after delivery, and RAI requires stopping or substantially reducing breastfeeding (I-131 accumulates in the breast). With a history of thyroid cancer, pregnancy does not worsen the prognosis but requires tighter TSH control (often < 0.5 or < 0.1 mIU/L depending on recurrence risk) and a 25–50% increase in levothyroxine dose, as in hypothyroidism (PMID 28056690).

🌀

Who should see a doctor first

▸Pregnant on levothyroxine — do not stop it "because you are pregnant": quite the opposite, the dose typically increases by 25–30%. ▸Overt hypothyroidism (TSH above the pregnancy range + low fT4) — treatment is started without delay. ▸TSH < 0.1 mIU/L in the 1st trimester — physiology is first distinguished from Graves' disease: thionamides are contraindicated in GTT. ▸Iodine — not alcoholic Lugol's solution and not kelp: uncontrolled doses, risk of overdose.

🌀

Bottom line

Pregnancy and thyroid disease call for trimester-by-trimester tactics with trimester-specific targets: preparation before conception, checks about every 4 weeks until mid-pregnancy and once more near week 30, and an iodine supplement of 150 µg/day as potassium iodide (women on levothyroxine do not need to start it). This is the ATA 2017 baseline (PMID 28056690) that reduces risks for mother and fetus; everything else is individualized tactics, which can be tailored at a consultation.

🌀

About the author

I am Dr. Vladimir Pereligyn, endocrinologist and researcher. I specialize in endocrine, metabolic, and autoimmune protocols with a holistic approach and individualized lab diagnostics. Book a consultation — universum.earth/consultation. Daily clinical breakdowns — @md_pereligyn_thyroid.

🌀

Sources

• Alexander EK et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017. PMID 28056690
• Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation. Endocr Rev 1997. PMID 9183570
• Haddow JE et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999. PMID 10451459
• Abalovich M et al. Management of subclinical hypothyroidism during pregnancy. J Clin Endocrinol Metab 2007. PMID 17948378
• Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab 2012. PMID 22312089
• Negro R et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease. J Clin Endocrinol Metab 2006. PMID 16621910
• Yassa L et al. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab 2010. PMID 20463094
• Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013. PMID 24622372
• Andersen SL et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013. PMID 24151287
• Iijima S. Pitfalls in the assessment of gestational transient thyrotoxicosis. Gynecol Endocrinol 2020. PMID 32301638
• Lazarus JH et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012. PMID 22316443

🌀